Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Metalidis C et al. | Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. | 2011 | Transplantation | pmid:21544031 |
Shihab FS et al. | Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study. | 2008 | Transplantation | pmid:18475181 |
Ekberg H | Calcineurin inhibitor sparing in renal transplantation. | 2008 | Transplantation | pmid:18813097 |
Fischer L et al. | Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. | 2015 | Transplantation | pmid:26151607 |
Shirakata Y et al. | Inhibitory effect of plasma FKBP12 on immunosuppressive activity of FK506. | 1995 | Transplantation | pmid:8545894 |
Leroy-Matheron C et al. | Inhibitor against coagulation factor V after liver transplantation. | 1999 | Transplantation | pmid:10532550 |
Takaya S et al. | The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. | 1992 | Transplantation | pmid:1371195 |
Ouyang J et al. | Effect of a novel inducible nitric oxide synthase inhibitor in prevention of rat chronic aortic rejections. | 2005 | Transplantation | pmid:15912108 |
Abbott KC et al. | New-onset gout after kidney transplantation: incidence, risk factors and implications. | 2005 | Transplantation | pmid:16340779 |
Villanueva G and Baldwin D | Rosiglitazone therapy of posttransplant diabetes mellitus. | 2005 | Transplantation | pmid:16340782 |
Koneru B et al. | Blood transfusions in liver recipients: a conundrum or a clear benefit in the cyclosporine/tacrolimus era? | 1997 | Transplantation | pmid:9197350 |
Shihab FS et al. | Donor preconditioning with a calcineurin inhibitor improves outcome in rat syngeneic kidney transplantation. | 2009 | Transplantation | pmid:19202436 |
Bayer ND et al. | Association of metabolic syndrome with development of new-onset diabetes after transplantation. | 2010 | Transplantation | pmid:20724958 |
Murase N et al. | Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. | 1990 | Transplantation | pmid:1696405 |
Kiuchi T et al. | A hepatic graft tuberculosis transmitted from a living-related donor. | 1997 | Transplantation | pmid:9089234 |
Propper DJ et al. | FK506--its influence on anti-class 1 MHC alloantibody responses to blood transfusions. | 1990 | Transplantation | pmid:1696409 |
Maruyama M et al. | Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells. | 1990 | Transplantation | pmid:1696410 |
Newell KA et al. | Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. | 1996 | Transplantation | pmid:8779685 |
Heilman RL et al. | Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. | 2011 | Transplantation | pmid:21775930 |
Bellon H et al. | The Effect of Immunosuppression on Airway Integrity. | 2017 | Transplantation | pmid:28471870 |
Lufft V et al. | Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. | 1996 | Transplantation | pmid:8779695 |
Barten MJ et al. | Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. | 2004 | Transplantation | pmid:15114077 |
Jain A et al. | Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus. | 2000 | Transplantation | pmid:10653398 |
Yamazaki S et al. | Transplantation-related thrombotic microangiopathy triggered by preemptive therapy for hepatitis C virus infection. | 2008 | Transplantation | pmid:18852671 |
Kiuchi T | CNIs: immediate benefits but storing problems for the future? | 2008 | Transplantation | pmid:18946338 |
Couzi L et al. | Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients. | 2008 | Transplantation | pmid:18946343 |
Stevens RB et al. | A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes. | 2015 | Transplantation | pmid:25083614 |
Kaufman DB et al. | The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome. | 1995 | Transplantation | pmid:7541579 |
Eckhoff DE et al. | The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. | 2000 | Transplantation | pmid:10830224 |
Hanto DW and Chudzinski R | What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus? | 2009 | Transplantation | pmid:19155968 |
Markus PM et al. | Effects of in vivo treatment with FK506 on natural killer cells in rats. | 1991 | Transplantation | pmid:1707562 |
Opelz G and Döhler B | Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. | 2008 | Transplantation | pmid:18698238 |
Steinmüller TM et al. | The effect of FK506 versus cyclosporine on glucose and lipid metabolism--a randomized trial. | 1994 | Transplantation | pmid:7524203 |
Singh N et al. | Infectious complications in liver transplant recipients on tacrolimus. Prospective analysis of 88 consecutive liver transplants. | 1994 | Transplantation | pmid:7524204 |
Roberti I et al. | Evidence that the systematic analysis of bile cytology permits monitoring of hepatic allograft rejection. | 1992 | Transplantation | pmid:1384182 |
Pape E et al. | Management of Tacrolimus-Telaprevir Drug-Drug Interaction in a Liver Transplant Patient With Hepatitis C Virus: Practical Considerations. | 2015 | Transplantation | pmid:26308424 |
Gruessner RW et al. | Donor-specific portal blood transfusion in intestinal transplantation: a prospective, preclinical large animal study. | 1998 | Transplantation | pmid:9701258 |
Pascual J et al. | Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. | 2010 | Transplantation | pmid:20335831 |
Farley DE et al. | The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. | 1991 | Transplantation | pmid:1713360 |
Raggi MC et al. | Customized mycophenolate dosing based on measuring inosine-monophosphate dehydrogenase activity significantly improves patients' outcomes after renal transplantation. | 2010 | Transplantation | pmid:21076373 |
Vathsala A et al. | The immunosuppressive antagonism of low doses of FK506 and cyclosporine. | 1991 | Transplantation | pmid:1713361 |
Sahara H et al. | Beneficial effects of perioperative low-dose inhaled carbon monoxide on pulmonary allograft survival in MHC-inbred CLAWN miniature swine. | 2010 | Transplantation | pmid:21076382 |
Min SI et al. | CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. | 2010 | Transplantation | pmid:21076384 |
Chan L et al. | Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. | 2008 | Transplantation | pmid:18360262 |
Ueki S et al. | Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin. | 2006 | Transplantation | pmid:17198266 |
Murase N et al. | Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. | 1993 | Transplantation | pmid:7678353 |
Herold KC et al. | Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. | 1993 | Transplantation | pmid:7678356 |
Gruber SA and Doshi MD | Conversion to sirolimus in African American renal allograft recipients undergoing early steroid withdrawal: intermediate-term risks and benefits. | 2010 | Transplantation | pmid:20440195 |
Burger CI et al. | Case report: drug interaction between tacrolimus and amiodarone with QT prolongation. | 2010 | Transplantation | pmid:20440199 |
Krämer BK et al. | Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial. | 2012 | Transplantation | pmid:22858806 |